Drug therapy for BC depends on the molecular subtype: endocrine therapy for luminal BC, anti-HER2 drugs for HER2 BC, and chemotherapy and immune-checkpoint inhibitors (ICIs) for TNBC. Here, ERBB2 is linked to breast cancer.